of patients are not satisfied with weight loss solutions they’ve tried|footnote-311|
A fast and efficient procedure
The Elipse Balloon is swallowed during a standard 20-minute consultation.|footnote-89| It passes out naturally approximately 16 weeks later.|asterisk-293|
Elipse is a breakthrough in simplicity: there is no surgery, no endoscopy|asterisk-293| and no anaesthesia required. The programme offers demonstrated efficacy alongside the convenience of a walk-in placement. Your patient enjoys the privacy of fast and effective outpatient treatment at your clinic. This personalised approach means no one in their immediate circle needs to know they have had the placement.
Effective results
After approximately 16 weeks of Elipse therapy, patients lose an average of 10 to 15kgs (1.57 to 2.36 stone).|footnote-90| |footnote-302| |footnote-296| |footnote-297| |footnote-295| |footnote-298| |footnote-299| |footnote-300| |footnote-301| |footnote-303|
When coupled with a 16-week intensive lifestyle modification, Elipse leads to significant weight loss compared to lifestyle modification alone.
However, a temporary balloon does not mean temporary weight loss. One study showed that 72% of average weight loss can be sustained after 12 months.|footnote-90|
Multidisciplinary support
Patients receive medical and nutritional support for the duration of the programme, along with a smartphone app and a connected scale to track progress.
Elipse is more than "just a balloon". It’s a fully supported weight-loss programme that is tailored to individual needs. It provides your patients with the nutritional support and exercise guidance they need to make life-changing habits to kick-start their weight-loss journey.|asterisk-307|
A revolutionary material
The balloon material is flexible enough to fold into a capsule and safely pass through the GI tract, yet durable enough to spend 16 weeks in the stomach|footnote-90| |footnote-296| |footnote-314|
Swallowing the balloon
The capsule is swallowed along with a thin delivery catheter that facilitates filling. A study shows 99.9% of patients are able to swallow the device, with only 32% requiring stylet assistance.|footnote-302|
The fill valve
The fill valve is made from thin film that seals shut after the delivery catheter is removed.
The release valve
This is made from a thin film and a degradable filament. The release valve progressively weakens and then opens at a pre-determined time to allow the balloon to empty.|footnote-90| |footnote-296| |footnote-314| The empty balloon then passes through the GI tract naturally or may be vomited in a very small number of patients. Vomiting of the balloon has not been associated with any reported adverse events to date.
An excellent safety profile with proven efficacy
The largest Elipse data collection to date featured|footnote-302|
1623 consecutive patients
19 centres
7 countries
At 4 months
Total Body Weight Loss was
13.6% ±5,7%
Mean Weight Loss
12.9kgs ±6.5kgs
BMI reduction
4.9kg/m² ±3.3kg/m2
All metabolic parameters improved; triglycerides, LDL cholesterol and level of blood sugar (measured in a subset of 407 patients)
99.9%
of patients were able to swallow the device
Discover the Allurion Master Classes
Watch our experts discuss clinical updates, international market research and so on..
Go
Support from day 1
- Place your first 10 balloons with the support of the Allurion team
- Use in-clinic communication tools
- Get support to help you create a tailored, multidisciplinary Elipse programme
Benefit from Allurion’s expertise
- Clinical expertise
- Research
- Allurion Academy
- Staff training
- Online support
- Customer care manager
Improve patient engagement and follow-up
- Long-term programme
- Connected smart scale
- Allurion app
Publications & clinical studies
The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients
R. Ienca, Mohammed Al Jarallah, Adelardo Caballero, Cristiano Giardiello, Michele Rosa, Sébastien Kolmer, Hugues Sebbag, Julie Hansoulle, Giovanni Quartararo, Sophie Al Samman Zouaghi, Girish Juneja, Sébastien Murcia, Roman Turro, Alberto Pagan, Faruq Badiuddin, Jérôme Dargent, Pierre Urbain, Stefan Paveliu, Rita Schiano di Cola, Corrado Selvaggio & Mohammed Al Kuwari
The Safety and Efficacy of Procedureless Gastric Balloon: a Study Examining the Effect of Elipse Intragastric Balloon Safety, Short and Medium Term Effects on Weight Loss with 1-Year Follow-Up Post-removal.
Jamal MH, Almutairi R, Elabd R, AlSabah SK, Alqattan H, Altaweel T.
The safety and efficacy of the procedureless intragastric balloon
Salman Alsabah, M.B.A., F.R.C.S.C., F.A.C.S
Eliana Al Haddad, M.D.
Shehab Ekrouf, F.R.C.S.
Ahmad Almulla, F.R.C.S.
Saud Al-Subaie, F.R.C.S.
Mubarak Al Kendari, F.R.C.S
A prospective pilot study of the efficacy and safety of Elipse intragastric balloon: A single-center, single-surgeon experience.
Al-Subaie S., Khalifa S., Buhaimed W., Al-Rashidi S.
Safety and Efficacy of a New Swallowable Intragastric Balloon Not Needing Endoscopy: Early Italian Experience.
Genco, Ernesti, Ienca, Casella, Mariani, Francomano, Soricelli, Lorenzo, Monti
The Elipse Balloon, a swallowable gastric balloon for weight loss not requiring sedation, anesthesia or endoscopy: a pilot study with 12-month outcomes
Ioannis Raftopoulos, M.D., Ph.D., F.A.C.S., F.A.S.M.B.S., Andreas Giannakou, M.D.
Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study
Evzen Machytka, Shantanu Gaur, Ram Chuttani, Martina Bojkova, Tomas Kupka, Marek Buzga, Andreas Giannakou, Kandiliotis Ioannis, Elisabeth Mathus-Vliegen, Samuel Levy, Ioannis Raftopoulos
Elipse™, a Procedureless Gastric Balloon for Weight Loss: a Proof-of-Concept Pilot Study
Evzen Machytka, Ram Chuttani, Martina Bojkova, Tomas Kupka, Marek Buzga, Kathryn Stecco, Samuel Levy & Shantanu Gaur
How can we help?
We’re here to answer any questions you may have.
In case of a medical emergency or other medical questions, please contact your Elipse clinic or local healthcare provider.